Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Cerebral infarction except cardiac source of embolism based on the NINDSⅢclassification~2. Neurological signs persisting≧ 1 day from onset~3. Defined onset of symptoms, and stable condition at the period of enrollment~4. CT or MRI detection of responsible site~5. age≧20~6. Systolic pressure≦180 mmHg, Diastolic pressure≦110 mmHg~7. The maximum intensity of platelet aggregation is above 15 % induced by serotonin (1µM) and epinephrine (3µM) on the day of prior to the first medication~8. Written informed consent must be obtained from the patients before enrollment into the study~Exclusion Criteria:~1. Functional outcome at randomization: Modified Rankin Scale=4, 5~2. Previous or planned for vascular surgery to cerebral infarction~3. History of intracranial hemorrhage~4. History of systemic bleeding, or other history of bleeding diathesis or coagulopathy~5. With severe complications ( renal or hepatic insufficiency, heart failure, hemopathy, and so on )~6. Treating malignant tumor~7. Pregnant or possibly pregnant women, or nursing mothers~8. History of sarpogrelate sensitivity~9. Previously entered in other clinical trials within 3 months~10. Less than 3 months since any other clinical trial~11. Judged by investigator to be unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group L (Type: EXPERIMENTAL): 25mg sarpogrelate
- group M (Type: EXPERIMENTAL): 50mg sarpogrelate
- group H (Type: EXPERIMENTAL): 100mg sarpogrelate

Based on this trial design, predict the completion outcome and termination type (if applicable).